Press Release Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Jul 29
Press Release Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) Jul 28